univers coverag
calendar event
medacorp puls call on-going migrat toward valu base
medacorp puls call get straight trend dental edt
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
medic meet american academi otolaryngolog head neck surgeri aao-
hnsf annual meet intern societi research iser biennial meet
leadership seri busi sourc lt upsid
ev/sal multipl sale
bottom line last friday host med-tech leadership seri call chairman
presid ceo scott ward rhonda robb cfo jeff point call discuss
outlook across long-term growth vector -- core orbit atherectomi system
busi intern expans new product launch next five year view
call even bullish expect -- near-term guidanc long-
term growth opportun ward categor long-term outlook ambiti highlight
believ could ultim signific upsid driver core busi -- peripher
coronari overal convers reinforc view repres sustain
double-digit growth stori next year core busi continu believ
compani signific competit advantag calcifi below-the-kne lesion
within peripher drive above-market growth well grow market-lead
posit highli under-penetr coronari market us long-term guidanc
achiev project long-term growth core pad cad busi leav
room upside/offset execut risk new product launch addit recent
manag chang busi develop activ sale forc restructur posit
compani well improv execut acceler growth go forward
could cch cellulit meaning opportun endo
ev/ebitda multipl
bottom line believ rel high likelihood success endo two
xiaflex upcom collagenas clostridium histolyticum cch cellulit trial readout
sever unknown could influenc sale potenti cch base
preliminari assess believ could peak sale opportun
appreci qtd improv sentiment around gener segment manag
deliv strong rais ep guidanc also
believ sentiment around stock due upcom cch data
pt cch current result posit expect least upsid
stock news top see upsid potenti time anoth
strong commerci execut although note need get better visibl endo
commerci strategi get comfort upsid potenti reiter op pt
believ rel high likelihood two phase cch trial posit
cch could offer less invas treatment potenti robust efficaci current avail
believ market opportun exist cch drive peak sale potenti
current assum risk-adjust sale
medacorp specialist feedback suggest current penetr cellulit treatment low
potenti growth better treatment option
sever variabl critic realiz sale potenti cch unknown
current look greater visibl endo make progress
rule higher blue-ski scenario sale much higher howev would need
clariti above-ment factor get comfort
posit transform continu stock seem fairli valu
adjust ep
bottom line attend investor day new york friday overal come
away event posit fundament compani though stock appear
fairli valu like manag work mani bug core
system satisfact level among provid client improv dramat past
year firm recent acquisit entrada eagl dream healthfus seem
pay qualiti book past quarter appear good appear like
ceo rusti frantz new execut team inde abl turn around
rare see hcit turn-around result stabil busi elimin
dividend increas leverag recent deal seem work well despit
posit reduc estim slightli due higher cog
assumpt furthermor pt assum price-to-earnings multipl high
rel histori peer result maintain mp formerli qsii
qualiti book seem high
non-gaap ep exclud acquir amort acquisit cost stock comp litig cost
outlook still conserv consum growth engin invest dx pt
bottom line view high growth research tool consum engin
diversifi diagnost recent acquisit exosom diagnost
 expect almost doubl revenu revenu
today deliv adjust oper incom recent
acquisit exosom dx technolog drive near-term outlook
lever adopt exosom epi exodx prostat intelliscor assay link market
help reduc unnecessari biopsi significantli rule patient grey zone
initi test rais revenu estim believ
experi bp near-term oper margin dilut price well-awar
paid high growth asset
exosom could deliv signific upsid long-term investor like watch near-term reimburs
still much high growth high margin consum lever stori
outlook conserv view still account acquisit long-term
revenu ep exclud charg amort intang
construct ssiem data brineura-lik pathway unclear
review surviv fittest turnaround diamond
top question manag mco facil payor servic
fda consid total data approv data less
use discount rate termin growth rate
doj pois approv cvs-aet ci-esrx ahead schedul wsj
review red flag onward upward chock full
shine nsr-rpgr suggest potenti derisk data ahead pt
dcf analysi discount rate termin growth rate
manag meet highlight turn-around effort progress pt
vertic healthcar merger reportedli on-track regulatori approv
kol discuss oncolyt virus approach
dcf analysi revenu multipl dr tgr
fda accept ind us enrol begin
major overhang remov hsgx phase trial fail primari
price-to-earnings ep
impli ev/sal
sept teva fremanezumab anti-cgrp prevent migrain pdufa
manag remain confid time approv fremanezumab
septemb pdufa date follow recent issuanc new letter fda
celltrion facil discuss medacorp current good manufactur
practic cgmp specialist continu believ low likelihood
observ made latest letter juli inspect highlight issu like
impact product qualiti patient safeti result believ celltrion unlik
yet made adequ progress resolv outstand warn letter
link recent analysi latest letter
obsv nolasiban oral oxytocin receptor antagonist assist
nolasiban target ivh market larg grow need treatment
implant phase data demonstr direct improv
pregnanc rate day day pregnanc show stat sig improv
pool data
believ data encourag may even suffici approv eu
along posit sub-group analysi ph
look manag provid greater regulatori clariti requir approv
us eu
believ risk-reward skew upsid ahead upcom catalyst
addit look live birth rate data implant posit
go long way improv commerci potenti
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi link
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
esmo adap present initi efficaci data t-cell receptor tcr
program multipl solid tumor type urotheli melanoma head neck ovarian nsclc
adap clinical-stag biotechnolog compani pioneer develop t-
cell base immunotherapi cancer
compani tcr platform could potenti address solid tumor view
transform cell therapi space success
adap proprietari platform enabl gener engin tcr-base cell therapi
permit target wide rang antigen exploit monoclon
antibodi chimer antigen receptor -t
project probability-weight nsclc scchn bladder sale
expect potenti signific stock price reaction presentaton
initi ph i/ii efficaci data tcr studi non-smal
cell lung cancer nsclc tripl tumor studi
present phase ii data tazemetostat epithelioid sarcoma es
also tumor cohort object respons rate durat
respons data essenti plan nda file
partner lysa present phase ib safeti pk data combin
tazemetostat chemotherapi r-chop front-lin diffus larg cell lymphoma
dlbcl cohort includ patient stratifi mutat
statu one two on-going tazemetostat trial dlbcl compani
recent announc de-priorit studi indic
tazemetostat clinic program still partial hold us franc germani
prompt respons regulatori author resolut clinic hold critic
time enrol patient follicular lymphoma trial project snda
imgn lead proprietari product candid mirvetuximab soravtansin current phase
develop forward-i single-ag platinum-resist ovarian cancer
addit on-going forward-ii phase i/ii studi evalu drug
combin avastin keytruda carboplatin avastin tripl studi advanced/
present data forward-ii avastin combin american societi
clinic oncolog respons rate substanti improv
mirvetuximab monotherapi mark improv progression-fre
surviv durat respons
plan present addit phase ii expans data patient treat
medium high fr-alpha express part keytruda combin
medacorp kol spoken express mix view combin
especi combin keytruda given limit success ovarian cancer
oct dupix asthma indic pdufa
expect dupix sbla approv asthma adult/adolesc patient
consid import catalyst stock
subgroup eosinophil asthma patient dupix confer
exacerb reduct benefit greater lung function benefit approv
-- market drug class eosinophil asthma
believ total product consensu revenu expect surpass
revenu contribut eosinophil asthma patient
given data prefer partner sni focu data label effort
eosinophil patient order highlight superior medicin
full analysi refer note dupi asthma estim dont reflect superior
vs eosinophil asthma outperform
tx award expect announc octob effect date
new contract expect januari
current oper region tx estim market share
submit bid region compani remain posit around retent
least exist tx region
reprocur could mean mm revenu beneficiari
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
sourc leerink research compani inform factset price prior day
pdufa teva fremanezumab cgrp migrain
fda adcom neurolog devic panel medic devic
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefenacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
american academi otolaryngolog head neck surgeri aao-hnsf
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
chines societi clinic oncolog zlab
data present
zlab brivanib ph ii result
european societi retina specialist euretina nite
american colleg clinic pharmacolog
intern associ studi lung cancer
feder surgeri obes metabol disord
american academi implant dentistri
american societi head neck radiolog
european societi paediatr endocrinolog
american societi bone miner research asnd cmta
american societi human genet arql
european societi medic oncolog adap imdz iph
go live az
model model nite recent updat pleas contact leerink
repres wish review
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
 west coast alzheim kol provid discourag view amyloid aaic
 half full half empti alzheim diseas puls call takeaway market perform
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
 glucagon rescu progress schedul outperform
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
outperform
outperform
deal capac
outperform
outperform
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 vyxeo survey suggest outpati usag grow outperform
 awak w/ solriamfetol rais est follow medacorp survey pt
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey in-lin out-year trend quarter look
ew thv link link
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
teva rais austedo sale analysi posit medacorp physician survey
 leadership seri growth momentum sustain stemi data catalyst
 open ablat atriclip drive near term growth mi longer term
 leadership seri call highlight upsid potenti neuromodul outperform
 differenti poc signific runway impli upsid pt
 leadership seri growth acceler strong gener outperform
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
